Skip to main content

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

Abstract

A critical gap exists in determining treatment preferences and treatment satisfaction from patient perspectives, which is paramount to achieving therapeutic success. The objective of this systematic review is to determine factors influencing treatment preferences and treatment satisfaction among psoriasis patients. PubMed, EMBASE, and Web of Science databases were searched between November 1, 2010, and December 1, 2017. Observational and interventional research studies published in the English language that discussed patient preferences and patient satisfaction in the treatment of psoriasis were reviewed and synthesized. We utilized data on treatment preferences and treatment satisfaction from 35,388 psoriasis patients based on 60 articles from the years 2010 to 2017. Treatment preferences were heterogeneous and changed over time among psoriasis patients. Across all treatment modalities, the most important treatment attributes were treatment location, probability of improvement, and delivery method. For biologics specifically, the most important attributes were risk of adverse events and probability of treatment benefit. Factors that influenced patients’ preferences for certain treatments included age, sex, comorbidities, disease duration, and prior treatments. Notably, some psoriasis patients placed higher importance on a treatment’s process attributes (e.g., access and delivery) over its outcome attributes (e.g., efficacy). Overall, patient satisfaction with existing therapies remains modest; however, those treated with biologic agents exhibited highest treatment satisfaction over oral therapy, phototherapy, and topical therapy.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Alcusky M, Lee S, Lau G, Chiu GR, Hadker N, Deshpande A, Fleming S, Vance N, Fakharzadeh S (2017) Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. Dermatol Ther (Heidelb) 7(4):463–483

    Article  Google Scholar 

  2. 2.

    Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG (2013) Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003–2011. JAMA Dermatol 149(10):1180–1185

    Article  PubMed  Google Scholar 

  3. 3.

    Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12. https://doi.org/10.1186/1477-7525-2-12

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K (2014) Nail assessment in psoriasis and psoriatic arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol 170(3):591–598

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K, Augustin M (2016) Patient-relevant needs and treatment goals in nail psoriasis. Qual Life Res 25(5):1179–1188

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, Thaci D, Augustin M (2016) Patient-relevant treatment goals in psoriasis. Arch Dermatol Res 308(2):69–78

    Article  PubMed  Google Scholar 

  7. 7.

    Callis Duffin K, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, Shin DB, Van Voorhees AS, Gelfand JM (2014) Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol 170(3):672–680

    Article  PubMed  Google Scholar 

  8. 8.

    Cazzaniga S, Lo Scocco G, Schincaglia E, Mercuri SR, Chimenti S, Saraceno R, Naldi L (2014) Double-blind, within-patient, randomized, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar psoriasis. J Dermatolog Treat 25(1):26–29

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Christophers E, Segaert S, Milligan G, Molta CT, Boggs R (2013) Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat 24(3):193–198

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Courtenay M, Carey N, Stenner K, Lawton S, Peters J (2011) Patients’ views of nurse prescribing: effects on care, concordance and medicine taking. Br J Dermatol 164(2):396–401

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Driessen RJB, Bisschops LA, Adang EMM, Evers AW, van de Kerkhof PCM, de Jong E (2010) The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 162(6):1324–1329

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Eastman WJ, Malahias S, Delconte J, DiBenedetti D (2014) Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis 94(1):46–53

    PubMed  Google Scholar 

  13. 13.

    Eliasson L, Bewley AP, Mughal F, Johnston KM, Kuznik A, Patel C, Lloyd AJ (2017) Evaluation of psoriasis patients’ attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments. Patient Prefer Adher 11:353–362. https://doi.org/10.2147/PPA.S121838

    Article  Google Scholar 

  14. 14.

    Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, van de Kerkhof PC (2008) Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 59(6):1009–1016

    Article  PubMed  Google Scholar 

  15. 15.

    Ferwerda M, Van Beugen S, Van Burik A, Van Middendorp H, De Jong EMGJ., Van De Kerkhof PCM, Van Riel PLCM., Evers AWM (2013) What patients think about E-health: patients’ perspective on internet-based cognitive behavioral treatment for patients with rheumatoid arthritis and psoriasis. Clin Rheumatol 32(6):869–873

    Article  PubMed  Google Scholar 

  16. 16.

    Feuerhahn J, Blome C, Radtke M, Augustin M (2012) Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 304(6):433–441

    Article  PubMed  Google Scholar 

  17. 17.

    Finch T, Shim TN, Roberts L, Johnson O (2015) Treatment satisfaction among patients with moderate-to-severe psoriasis. J Clin Aesthet Dermatol 8(4):26–30

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Franzke N, Montenbruck M, Langenbruch AK, Beikert FC, Kresken J, Augustin M (2013) Drug supply for psoriasis—results from a national pharmacy network. J Dtsch Dermatol Ges 11(7):638–643

    PubMed  Google Scholar 

  19. 19.

    Fruhauf J, Schwantzer G, Ambros-Rudolph CM, Weger W, Ahlgrimm-Siess V, Salmhofer W, Hofmann- Wellenhof R (2012) Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis. Australas J Dermatol 53(1):41–46

    Article  PubMed  Google Scholar 

  20. 20.

    Gisondi P, Farina S, Giordano MV, Zanoni M, Girolomoni G (2012) Attitude to treatment of patients with psoriasis attending SPA center. G Ital Dermatol Venereol 147(5):483–489

    CAS  PubMed  Google Scholar 

  21. 21.

    Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58(5):851–864

    Article  PubMed  Google Scholar 

  22. 22.

    Hashimoto T, Kawakami T, Tsuruta D, Hamada T, Natsuaki Y, Fukuda S, Koga H, Sogame R, Ohyama B, Ono F, Karashima T, Nakama T, Dainichi T, Ishii N, Yasumoto S (2012) Low-dose cyclosporin improves the health-related quality of life in Japanese psoriasis patients dissatisfied with topical corticosteroid monotherapy. Australas J Dermatol 53(3):202–206

    Article  PubMed  Google Scholar 

  23. 23.

    Hauber AB, Gonzalez JM, Schenkel B, Lofland JH, Martin S (2011) The value to patients of reducing lesion severity in plaque psoriasis. J Dermatolog Treat 22(5):266–275

    Article  PubMed  Google Scholar 

  24. 24.

    Hjortsberg C, Bergman A, Bjarnason A, Heikkila H, Hjelmgren J, Svensson A, Tennvall GR (2011) Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. Acta Derm Venereol 91(4):409–414

    Article  PubMed  Google Scholar 

  25. 25.

    Hong CH, Papp KA, Lophaven KW, Skallerup P, Philipp S (2017) Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol 31(11):1876–1883

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Ito K, Imafuku S, Nakayama J (2013) Therapeutic preferences are different in psoriatic and atopic dermatitis patients: a questionnaire-based study. J Dermatol 40(4):292–294

    Article  PubMed  Google Scholar 

  27. 27.

    Iversen L, Jakobsen HB (2016) Patient preferences for topical psoriasis treatments are diverse and difficult to predict. Dermatol Ther (Heidelb) 6(2):273–285

    Article  Google Scholar 

  28. 28.

    Jong MC, Ermuth U, Augustin M (2013) Plant-based ointments versus usual care in the management of chronic skin diseases: a comparative analysis on outcome and safety. Compliment Ther Med 21(5):453–459

    Article  Google Scholar 

  29. 29.

    Korman NJ, Zhao Y, Lu J, Tran MH (2015) Psoriasis disease severity affects patient satisfaction with treatment. Dermatol Online J 21(7):1–10

  30. 30.

    Krenzer S, Radtke M, Schmitt-Rau K, Augustin M (2011) Characterization of patient-reported outcomes in moderate to severe psoriasis. Dermatology 223(1):80–86

    Article  PubMed  Google Scholar 

  31. 31.

    Kromer C, Peitsch WK, Herr R, Schmieder A, Sonntag D, Schaarschmidt ML (2017) Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability. J Dtsch Dermatol Ges 15(2):189–200

    Google Scholar 

  32. 32.

    Kromer C, Schaarschmidt ML, Schmieder A, Herr R, Goerdt S, Peitsch WK (2015) Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PLoS One 10(6):e0129120

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Lambert J, Hol CW, Vink J (2014) Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study. J Eur Acad Dermatol Venereol 28(12):1723–1731

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Lambert J, Hol CW, Vink J (2015) Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol 29(12):2349–2355

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Lecluse LL, Tutein Nolthenius JL, Bos JD, Spuls PI (2009) Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 160(6):1340–1343

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    MacKenzie H, Thavaneswaran A, Chandran V, Gladman DD (2011) Patient-reported outcome in psoriatic arthritis: a comparison of Web-based versus paper-completed questionnaires. J Rheumatol 38(12):2619–2624

    Article  PubMed  Google Scholar 

  37. 37.

    Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58(5):826–850

    Article  PubMed  Google Scholar 

  38. 38.

    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R (2009) Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 60(4):643–659

    Article  PubMed  Google Scholar 

  39. 39.

    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R (2010) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 62(1):114–135

    Article  PubMed  Google Scholar 

  40. 40.

    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R (2009) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61(3):451–485

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Naldi L, Yawalkar N, Kaszuba A, Ortonne JP, Morelli P, Rovati S, Mautone G (2011) Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. Am J Clin Dermatol 12(3):191–201

    Article  PubMed  Google Scholar 

  42. 42.

    Paul C, Stalder JF, Thaci D, Vincendon P, Brault Y, Kielar D, Tebbs V (2012) Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 26(4):448–455

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, Chan D (2010) A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 49(12):1368–1375

    Article  PubMed  Google Scholar 

  44. 44.

    Poulin Y, Wasel N, Chan D, Bernstein G, Andrew R, Fraquelli E, Papp K (2012) Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician. Can Fam Physician 58(7):e390–e400

    PubMed  PubMed Central  Google Scholar 

  45. 45.

    Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70(3):512–516

    Article  PubMed  Google Scholar 

  46. 46.

    Radtke MA, Langenbruch A, Jacobi A, Schaarschmidt ML, Augustin M (2016) Patient benefits in the treatment of psoriasis: long-term outcomes in German routine care 2007–2014. J Eur Acad Dermatol Venereol 30(10):1829–1833

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Radtke MA, Schaefer I, Blome C, Augustin M (2013) Patient benefit index (PBI) in the treatment of psoriasis—results of the national care study “PsoHealth”. Eur J Dermatol 23(2):212–217

    PubMed  Google Scholar 

  48. 48.

    Radtke MA, Spehr C, Reich K, Rustenbach SJ, Feuerhahn J, Augustin M (2016) Treatment satisfaction in psoriasis: development and use of the PsoSat patient questionnaire in a cross-sectional study. Dermatology 232(3):334–343

    Article  PubMed  Google Scholar 

  49. 49.

    Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkila H, Jemec GB, Kragballe K, Miller IM, Svensson A (2013) Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol 93(4):442–445

    Article  PubMed  Google Scholar 

  50. 50.

    Reich K, Zschocke I, Bachelez H, de Jong EM, Gisondi P, Puig L, Warren RB, Mrowietz U (2015) Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol 29(6):1156–1163

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Renzi C, Di Pietro C, Tabolli S (2011) Participation, satisfaction and knowledge level of patients with cutaneous psoriasis or psoriatic arthritis. Clin Exp Dermatol 36(8):885–888

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Sandoval LF, Huang KE, Harrison J, Clark A, Feldman SR (2014) Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference. Cutis 94(6):304–309

    PubMed  Google Scholar 

  53. 53.

    Schaarschmidt ML, Kromer C, Herr R, Schmieder A, Goerdt S, Peitsch WK (2015) Treatment satisfaction of patients with psoriasis. Acta Derm Venereol 95(5):572–578

    Article  PubMed  Google Scholar 

  54. 54.

    Schaarschmidt ML, Kromer C, Herr R, Schmieder A, Sonntag D, Goerdt S, Peitsch WK (2015) Patient preferences for biologicals in psoriasis: top priority of safety for cardiovascular patients. PLoS One 10(12):e0144335

    Article  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Schaarschmidt ML, Herr R, Gutknecht M, Wroblewska K, Gerdes S, Sticherling M, Augustin M, Peitsch WK (2017) Patients’ and physicians’ preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare). Acta Derm Venereol. https://doi.org/10.2340/00015555-2834

    PubMed  Google Scholar 

  56. 56.

    Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goebeler M, Goerdt S, Peitsch WK (2011) Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 147(11):1285–1294

    Article  PubMed  Google Scholar 

  57. 57.

    Schaarschmidt ML, Umar N, Schmieder A, Terris DD, Goebeler M, Goerdt S, Peitsch WK (2013) Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol 27(2):187–198

    Article  PubMed  Google Scholar 

  58. 58.

    Schafer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M (2010) Concordance of the psoriasis area and severity index (PASI) and patient-reported outcomes in psoriasis treatment. Euro J Dermatol 20(1):62–67

    Google Scholar 

  59. 59.

    Schmieder A, Schaarschmidt ML, Umar N, Terris DD, Goebeler M, Goerdt S, Peitsch WK (2012) Comorbidities significantly impact patients’ preferences for psoriasis treatments. J Am Acad Dermatol 67(3):363–372

    Article  PubMed  Google Scholar 

  60. 60.

    Shikiar R, Rentz AM (2004) Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 7(2):204–215

    Article  PubMed  Google Scholar 

  61. 61.

    Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L, Wu JH (2014) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (1):Cd001431. https://doi.org/10.1002/14651858.CD001431.pub4

  62. 62.

    Sticherling M, Eicke C, Anger T (2013) Practicability of combined treatment with calcipotriol/betamethasone gel (Daivobet(R) Gel) and improvement of quality of life in patients with psoriasis. J Dtsch Dermatol Ges 11(5):420–427

    PubMed  Google Scholar 

  63. 63.

    Sylwestrzak G, Liu J, Stephenson JJ, Ruggieri AP, DeVries A (2014) Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits 7(2):71–81

    PubMed  PubMed Central  Google Scholar 

  64. 64.

    Tan J, Stacey D, Fung K, Barankin B, Bissonnette R, Gulliver W, Lui H, Shear N, Jackson C, Zhang XM (2010) Treatment decision needs of psoriasis patients: cross-sectional survey. J Cutan Med Surg 14(5):233–239

    Article  PubMed  Google Scholar 

  65. 65.

    Tan J, Wolfe B (2012) A patient decision aid for psoriasis based on current clinical practice guidelines. Arch Dermatol 148(6):718–723

    Article  PubMed  Google Scholar 

  66. 66.

    Tan J, Wolfe B (2014) Improved decisional conflict and preparedness for decision making using a patient decision aid for treatment selection in psoriasis: a pilot study. J Cutan Med Surg 18(2):114–118

    Article  PubMed  Google Scholar 

  67. 67.

    Torbica A, Fattore G, Ayala F (2014) Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics 32(2):209–223

    Article  PubMed  Google Scholar 

  68. 68.

    Umar N, Litaker D, Schaarschmidt M-L, Peitsch WK, Schmieder A, Terris DD (2012) Outcomes associated with matching patients’ treatment preferences to physicians’ recommendations: study methodology. BMC Health Serv Res 12:1. https://doi.org/10.1186/1472-6963-12-1

    Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Schollgen I, Terris DD (2013) Matching physicians’ treatment recommendations to patients’ treament preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol 27(6):763–770

    CAS  Article  PubMed  Google Scholar 

  70. 70.

    Umar N, Schoellgen I, Terris DD (2012) It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis. Patient Prefer Adherence 6:187–194. https://doi.org/10.2147/ppa.s29285

    Article  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Umar N, Yamamoto S, Loerbroks A, Terris D (2012) Elicitation and use of patients’ preferences in the treatment of psoriasis: a systematic review. Acta Derm Venereol 92(4):341–346

    Article  PubMed  Google Scholar 

  72. 72.

    Van Cranenburgh OD, De Korte J, Sprangers MAG, De Rie MA, Smets EMA (2013) Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol 169(2):398–405

    Article  PubMed  Google Scholar 

  73. 73.

    van den Reek JM, van Luumig PP, Otero ME, Zweegers J, van de Kerkhof PC, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, Seyger MM, Kievit W, de Jong EM (2014) Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. Br J Dermatol 170(5):1158–1165

    Article  PubMed  Google Scholar 

  74. 74.

    Vender R, Lynde C, Gilbert M, Ho V, Sapra S, Poulin-Costello M (2012) Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice. J Cutan Med Surg 16(6):407–416

    CAS  Article  PubMed  Google Scholar 

  75. 75.

    Zhang ML, Carter C, Olson WH, Johnson MP, Brenneman SK, Lee S, Farahi K (2017) Patient preference for dosing frequency based on prior biologic experience. J Drugs Dermatol 16(3):220–226

    PubMed  Google Scholar 

  76. 76.

    Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K (2014) Assessing adherence factors in patients under topical treatment: development of the topical therapy adherence questionnaire (TTAQ). Arch Dermatol Res 306(3):287–297

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Helena Winston for her efforts in the initiation portion of this project.

Funding

There were no funding sources that supported this work.

Author information

Affiliations

Authors

Contributions

AGF, CJW, and AWA had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: AWA and AGF. Acquisition, analysis, and interpretation of data: AWA, AGF, and CJW. Drafting of the manuscript: AWA, AGF, and CJW. Critical revision of the manuscript for intellectual content: AWA, AGF, and CJW. Statistical analysis: N/A. Obtained funding: N/A. Administrative, technical, or material support: N/A. Study supervision: AWA.

Corresponding author

Correspondence to April W. Armstrong.

Ethics declarations

Conflict of interest

The authors have no relevant conflicts of interest to declare. AWA serves as investigator and/or consultant to Abbvie, Amgen, Janssen, Merck, Novartis, Lilly, Celgene, and Pfizer.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This study did not require formal informed consent.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Florek, A.G., Wang, C.J. & Armstrong, A.W. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res 310, 271–319 (2018). https://doi.org/10.1007/s00403-018-1808-x

Download citation

Keywords

  • Psoriasis
  • Patient preference
  • Patient participation
  • Treatment satisfaction